Feb 8 (Reuters) - Glaxosmithkline Plc GSK.L :
* VIIV HEALTHCARE LAUNCHES EIGHTH PHASE III STUDY IN TWO-DRUG REGIMEN PROGRAMME FOR HIV-1 TREATMENT
* TANGO WILL SEEK TO ENROL APPROXIMATELY 550 ADULTS WITH HIV-1, FROM CLINICAL TRIAL SITES IN NORTH AMERICA, EUROPE, AUSTRALIA, AND JAPAN
* EXPECTS RESULTS OF TANGO IN 2019
* STUDY TO INVESTIGATE DOLUTEGRAVIR AND LAMIVUDINE IN PATIENTS WITH HIV WHO HAVE ACHIEVED VIRAL SUPPRESSION ON TENOFOVIR ALAFENAMIDE FUMARATE-BASED REGIMEN